Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 3Sarcoma 2Plasma cell 2Head & Neck 2Gastrointestinal 2Dermatologic 2CNS 2Breast 2Thoracic 1Genitourinary 1

Conditions

Carcinoma, Renal Cell 62Prostatic Neoplasms 35Kidney Neoplasms 18Carcinoma, Transitional Cell 17Melanoma 15Urinary Bladder Neoplasms 14Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Clear-cell metastatic renal cell carcinoma 11Colorectal Neoplasms 9Neoplasms 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Pancreatic Neoplasms 5Urogenital Neoplasms 4Small Cell Lung Carcinoma 4Endometrial Neoplasms 4Carcinoma, Merkel Cell 4Urethral Neoplasms 3Penile Neoplasms 3Neuroblastoma 3Liver Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Ureteral Neoplasms 2

Interventions

Cyclophosphamide 8pembrolizumab 6Filgrastim 5Busulfan 5fludarabine phosphate 4fludarabine 4Nivolumab 4Flow Cytometry 4Antilymphocyte Serum 4Alemtuzumab 4Tacrolimus 3Stem Cell Transplantation 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Mycophenolic Acid 3Melphalan 3Dexamethasone 3Carboplatin 3Biopsy 3Azacitidine 3valspodar 2atezolizumab 2aldesleukin 2X-Rays 2Vorinostat 2Vincristine 2Thiotepa 2Psychiatric Rehabilitation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Ipilimumab × Genitourinary × Clear all
NCT01445379 2019-12-17

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
33 enrolled
CNSGenitourinaryLymphoidSarcoma

Lymphoma, Wilms Tumor, Neuroblastoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡